MWC
ACRS icon

MBM Wealth Consultants’s Aclaris Therapeutics ACRS Stock Holding History

MBM Wealth Consultants’s Portfolio ACRS Stock Details ACRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-3,198
Closed -$12K – 125
2026
Q1 		$12K Buy
+3,198
New +$10.8K ﹤0.01% 230

Other funds holding ACRS

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BCM
BML Capital Management Zionsville, Indiana $176M AUM 123.21% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $2.05B AUM 161.37% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
DC
Decheng Capital Menlo Park, California $732M AUM 275.56% 1-Year Est. Return

MBM Wealth Consultants's ACRS Position: Q2 2026 in Review

MBM Wealth Consultants sold out of Aclaris Therapeutics (ACRS) in Q2 2026, closing a stake of 3,198 shares — an estimated $12K sold.

MBM Wealth Consultants first reported a position in ACRS in Q1 2026 and held it in 1 quarter. The position peaked at $12K in Q1 2026. 148 funds tracked by Wall St. Rank hold ACRS as of Q2 2026.

  • MBM Wealth Consultants reported no remaining Aclaris Therapeutics position as of Q2 2026 after selling out during the quarter.
  • MBM Wealth Consultants sold 3,198 Aclaris Therapeutics shares in Q2 2026, an estimated $12K.
  • MBM Wealth Consultants first reported a position in Aclaris Therapeutics in Q1 2026 and held it in 1 quarter.
  • MBM Wealth Consultants's Aclaris Therapeutics position peaked at $12K in Q1 2026.
  • 148 funds tracked by Wall St. Rank held Aclaris Therapeutics as of Q2 2026.

Based on MBM Wealth Consultants's 13F filing for Q2 2026, filed 24 Jul 2026.